Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (SEB) in Gorlin Syndrome Patients

Condition:   Basal Cell Nevus SyndromeInterventions:   Drug: patidegib;   Drug: vehicle gelSponsor:   PellePharm, Inc.Recruiting - verified May 2016

Source: ClinicalTrials.gov - April 27, 2016 Category: Research Source Type: clinical trials